טוען...
Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
Inhaled corticosteroids (ICSs) treatment combined with long-acting β(2)-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate...
שמור ב:
| הוצא לאור ב: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5654780/ https://ncbi.nlm.nih.gov/pubmed/29089754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S143656 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|